Dominican University of California
 

Presentation or Panel Title

McCune-Albright Syndrome and Tamoxifen: How Traditional Breast Cancer Medications are Being Used to Treat the Symptoms Associated with Precocious Puberty

Location

Guzman 202, Dominican University of California

Start Date

4-20-2017 2:35 PM

End Date

4-20-2017 3:00 PM

Department

Natural Sciences and Mathematics

Student Type

Undergraduate - Honors

Faculty Mentor

Diara Spain, Ph.D.

Presentation Format

Oral Presentation

Abstract/Description

Precocious puberty is a disorder characterized by the early onset of puberty in both males and females. Since the 1990s, multiple studies have found that the average age at which adolescents start puberty is steadily decreasing. There is growing concern that precocious puberty will lead to the decrease of both the ages of fertility and menopause in women affected by the disease. One probable cause of precocious puberty is McCune-Albright Syndrome (MAS), which is a rare genetic disease that affects the skin, bones, and endocrine glands. While traditional treatments of precocious puberty in MAS are generally seen as safe, they are not completely effective in alleviating the symptoms. Research studies have shown that Tamoxifen, which has traditionally been used as a treatment for breast cancer, successfully treats many of the symptoms of precocious puberty in girls with MAS. However, as Tamoxifen is a known carcinogen with relatively high toxicity, there is some apprehension regarding the possible long term effects of using it to treat precocious puberty. More natural analogs to Tamoxifen, such as Eryvarin H, are currently being researched with regard to the treatment of breast cancer. If these drugs are found to have a similar mechanism to Tamoxifen with fewer toxic effects, then they may also be applied to the treatment of precocious puberty in females with MAS.

This document is currently not available here.

Share

Import Event to Google Calendar

COinS
 
Apr 20th, 2:35 PM Apr 20th, 3:00 PM

McCune-Albright Syndrome and Tamoxifen: How Traditional Breast Cancer Medications are Being Used to Treat the Symptoms Associated with Precocious Puberty

Guzman 202, Dominican University of California

Precocious puberty is a disorder characterized by the early onset of puberty in both males and females. Since the 1990s, multiple studies have found that the average age at which adolescents start puberty is steadily decreasing. There is growing concern that precocious puberty will lead to the decrease of both the ages of fertility and menopause in women affected by the disease. One probable cause of precocious puberty is McCune-Albright Syndrome (MAS), which is a rare genetic disease that affects the skin, bones, and endocrine glands. While traditional treatments of precocious puberty in MAS are generally seen as safe, they are not completely effective in alleviating the symptoms. Research studies have shown that Tamoxifen, which has traditionally been used as a treatment for breast cancer, successfully treats many of the symptoms of precocious puberty in girls with MAS. However, as Tamoxifen is a known carcinogen with relatively high toxicity, there is some apprehension regarding the possible long term effects of using it to treat precocious puberty. More natural analogs to Tamoxifen, such as Eryvarin H, are currently being researched with regard to the treatment of breast cancer. If these drugs are found to have a similar mechanism to Tamoxifen with fewer toxic effects, then they may also be applied to the treatment of precocious puberty in females with MAS.